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The complement system plays an important role in the innate and acquired immune 
response against pathogens. It consists of more than 30 proteins found in soluble form 
or attached to cell membranes. Most complement proteins circulate in inactive forms and 
can be sequentially activated by the classical, alternative, or lectin pathways. Biological 
functions, such as opsonization, removal of apoptotic cells, adjuvant function, activation 
of B lymphocytes, degranulation of mast cells and basophils, and solubilization and 
clearance of immune complex and cell lysis, are dependent on complement activation. 
Although the activation of the complement system is important to avoid infections, it also 
can contribute to the inflammatory response triggered by immune complex deposition 
in tissues in autoimmune diseases. Paradoxically, the deficiency of early complement 
proteins from the classical pathway (CP) is strongly associated with development of 
systemic lupus erythematous (SLE) – mainly C1q deficiency (93%) and C4 deficiency 
(75%). The aim of this review is to focus on the deficiencies of early components of the 
CP (C1q, C1r, C1s, C4, and C2) proteins in SLE patients.
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SYSTeMiC LUPUS eRYTHeMATOSUS
Systemic lupus erythematous (SLE) is a systemic autoimmune disorder in which multiple autoanti-
bodies against cell nuclear constituents – DNA, histones, and ribonucleoproteins – are produced. The 
deposition of immune complexes in several organs, mainly kidney, skin, and joints, causes inflamma-
tion and tissue damage, producing a broad spectrum of clinical manifestations (1–3) (Table 1) (4). 
SLE classification criteria was defined by the American College of Rheumatology (ACR) in 1982 (5) 
and revised in 1997 (6). In 2012, the Systemic Lupus Collaborating Clinics (SLICC) validated the new 
classification criteria (4). SLE is classified by 4 out of 17 criteria (including at least one clinical and one 
immunological criterion) or by biopsy-proven lupus nephritis in presence of ANA or anti-dsDNA 
antibodies (Table 1) (4). Criteria are cumulative and do not need be present concurrently.
The etiopathogenesis of SLE depends on complement system activation triggered by the presence 
of immune complexes, leading to inflammation and complement proteins consumption. The acute 
or continuous low-grade chronic inflammation of lupus often predisposes patients to infections and 
cardiovascular diseases. Interaction of genetic background with environmental factors makes SLE one 
of the most complex diseases (7–11). SLE incidence ranges from 1 to 10 per 100,000 person-years and 
prevalence ranges from 20 to 70 per 100,000. SLE affects both sexes of every age, but predominates in 
TABLe 1 | Clinical and immunological criteria for SLe diagnostic 
[modified from Ref. (4)].
Clinical criteria
Acute cutaneous lupus
Chronic cutaneous lupus
Oral ulcers: in the absence of other causes
Non-scarring alopecia in the absence of other causes
Synovitis involving two or more joints, characterized by swelling or effusion OR 
tenderness in 2 or more joints and 30 min or more of morning stiffness
Serositis in the absence of other causes
Renal: 500 mg of protein/24 h urine or red blood cell casts
Neurologic symptoms in the absence of other known causes such as primary 
vasculitis, infection, and diabetes mellitus, including toxic-metabolic, uremia, 
and drugs
Hemolytic anemia
Leukopenia (<4000/mm3) or lymphopenia (<1000/mm3): in the absence of 
other known causes
Thrombocytopenia (<100,000/mm3) in the absence of other known causes
immunological criteria
Antinuclear antibodies (ANA) titers above laboratory reference range
Anti-dsDNA (double-strand DNA) titers above laboratory reference range. If titer 
was determined by ELISA consider twice above laboratory reference range
Anti-Sm
Anti-phospholipid antibody: any of the following lupus anticoagulant false-
positive rapid plasma reagin (RPR), medium, or high titer of anti-cardiolipin (IgA, 
IgG, or IgM) or anti-β2 glycoprotein I (IgA, IgG, or IgM) autoantibodies
Low complement: low plasma levels of C3, C4, or CH50
Direct Coombs test positive in the absence of hemolytic anemia
February 2016 | Volume 7 | Article 552
Macedo and Isaac SLE and Complement Deficiency
Frontiers in Immunology | www.frontiersin.org
women of child-bearing age with the highest incidence observed 
in African-Americans. The prevalence for men is approximately 
10% of that observed in women (10–12). The disease is extremely 
rare in children <5 years of age, which demands a more accurate 
investigation for genetic and immunodeficiency’s causes of 
SLE. Juvenile systemic lupus erythematous (JSLE – onset before 
16  years old) represents 15–20% of all SLE cases and differ in 
multiple aspects. JSLE is more severe, with higher incidence of 
nephritis, hematological disorders, photosensitivity, butterfly 
rash, and mucosal ulceration (13–17).
To study influence of genetic factors, Deapen et al. compared 
107 pairs of SLE twins. They found 24% of concordance in 45 
pairs of monozygotic while only 6% of concordance in dizygotic 
twins. This reinforces the importance of genetic predisposition to 
SLE, though less than first expected, indicating the influence of 
environmental factors as well (18).
One of the most remarkable genetic associations in SLE is the 
high frequency of deficiency of the early components of the com-
plement system classical pathway (CP), mainly C1q (90–93%), 
C1r/C1s (50–57%), C4 (75%), and C2 (10%) (19–22).
COMPLeMenT SYSTeM ACTivATiOn
The complement system participates in innate and acquired 
immunity. The proper activation of this system against micro-
organisms becomes clearly evident in complement immunodefi-
cient patients, who are highly susceptible to recurrent infections.
The complement system is formed by more than 30 proteins 
present in a soluble form or on the surface of cell membranes. 
Some proteins act in sequential activation by different pathways: 
alternative pathway (AP), lectin pathway (LP), and CP. All 
pathways can lead to activation of a common terminal pathway, 
generating a membrane attack complex (MAC). This activation 
is tightly regulated to avoid excessive consumption of comple-
ment and tissue injury. Complement proteins may also act as 
cell surface receptors mediating important interactions with 
immune cells.
The AP is initiated by hydrolysis of an intramolecular thioester 
bond located in the C3 alpha chain in the native molecule. Once 
this bond is broken, the native structural conformation of C3 is 
modified generating (C3H2O), which now exhibits previously 
hidden binding sites for Factor B leading to the formation of the 
C3H2OB complex. Factor D cleaves Factor B, releasing the frag-
ment Ba generating C3H2OBb. This complex has a catalytic site 
that cleaves C3 into C3a and C3b. C3b has a structural conforma-
tion that resembles C3H2O and therefore also binds to Factor B 
(23–27). C3bB is cleaved by Factor D, generating C3bBb (the sec-
ond C3-convertase) and releasing Ba in the fluid phase. Properdin 
binds to C3b in this complex and stabilizes C3-convertases of the 
AP, increasing their half-lives (26, 28–32). Properdin can also 
bind directly to the surface of certain pathogens (33) and initiates 
a new platform for deposition of C3-convertase (34–36).
The LP is initiated once lectins, such as mannose-binding lec-
tin (MBL) or ficolins (ficolin-1, ficolin-2, and ficolin-3), bind to 
microorganisms carbohydrates. MBL-associated serine proteases 
(MASP 1–3) (37–39) are complexed to MBL or ficolins and 
they cleave C4 and C2 (40, 41), generating the complex C4b2a 
(C3-convertase).
The CP is activated mainly by the presence of immune com-
plexes formed by IgM or IgG. However, other proteins, such as 
C1q, pentraxins, and C-reactive protein, can bind directly to 
pathogens or other particles and directly activate the CP even 
in the absence of specific antibodies. Once the immune complex 
is formed, C1q binds to the Fc portion of the immunoglobulin 
and immediately activates C1r, which activates C1s. Activated 
C1s cleaves C4 into C4a and C4b and later C2 already complexed 
to C4 (C4bC2) generating the C3-convertase (C4b2a), which 
cleaves C3 into fragments C3a and C3b (42, 43).
All pathways converge to the activation of C3 protein, which 
can be cleaved by all C3-convertases. C3b fragments can bind to 
several acceptor molecules including C3-convertases (C3bBbC3bn 
or C4b2aC3bn) generating C5-convertases, which cleave C5 into 
C5a and C5b. The next component, C6, binds to C5b, generat-
ing C5b6, which now promotes the incorporation of C7 to form 
C5b67. This complex binds firmly to the cell membrane and later 
C8 binds to C7 generating C5b678. This complex has lytic activity, 
which is incremented when several C9 molecules bind to form 
the MAC – a transmembrane pore (42, 44–46).
FUnCTiOnS OF THe COMPLeMenT 
SYSTeM
The activation of the complement system generates active pro-
teins and fragments that play important roles for the innate and 
acquired immune response (47–49): (a) production of opsonins: 
fragments C3b, iC3b, and C3d bind covalently to acceptor surfaces 
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and molecules and may act as a bridge between pathogens or 
host cells and complement receptors (CR1 and CR3) present on 
phagocytic cells. This property may facilitate pathogen killing 
and antigen presentation complexed to MHC products for T lym-
phocytes; (b) production of anaphylatoxins, chemotactic factors, 
and inflammatory modulators: fragments C3a and C5a released 
during complement activation can bind to C3aR or C5aR1 and 
C5aR2 receptors triggering mast cells or basophil degranulation 
(50, 51), leading to production and release of important inflam-
matory mediators. C3a and C5a recruit leukocytes to the inflam-
matory area. Besides its proinflammatory effects, C3a could act 
too as inflammatory modulator on neutrophils (52); (c) increase 
antibody production: antigen-bound C3d interacts with CR2 
and BCR on B lymphocytes that are activated, proliferates, and 
produces higher levels of specific antibodies (53). These coated 
antigens also bind to follicular dendritic cells (DCs), that trap 
them into germinal centers of lymphoid organs, and display them 
to B cells to selection of high-affinity B cells (54); (d) clearance 
of immune complexes: fragments C4b and C3b covalently bind to 
immune complexes. Erythrocyte-CR1 binds to C3b/C4b-coated 
immune complexes, which are removed from circulation in the 
spleen and liver; (e) cell lysis: the assembly of MAC (C5b6789n) 
forms a pore in the membrane surface, which leads to osmotic 
cell lysis; and (f) removal of apoptotic cells and debris: C1q (55), 
C4b, and C3b (56) enhance the ingestion of dead cells by phago-
cytes (57).
PATHOGeneSeS OF SLe: inADeQUATe 
ReMOvAL OF DeBRiS AnD ReDUCTiOn 
OF SeLF-TOLeRAnCe
Apoptosis is a fundamental event for embryogenesis, negative 
selection of T and B lymphocytes, and maturation of organs. 
This type of cell death is a coordinated process in which cells 
undergo cytoskeletal disruption, shrinkage, DNA fragmentation, 
and plasma membrane blebbing under active control so as not 
to trigger local inflammation. Production of anti-inflammatory 
cytokines, such as TGF-beta, after apoptosis is observed (58). 
Consequently to apoptosis, the cell membrane is modified, and 
internal phospholipids are exposed on the surface. Opsonization 
of apoptotic cells is mediated by C1q, C4b, C3b, pentraxins, 
and collectins. Phagocytic macrophage and DCs remove the 
opsonized apoptotic debris (58). While apoptosis takes place 
over a few hours, the removal of apoptotic debris is a very quick 
process, so as to avoid inflammatory response and activation of 
T lymphocytes (8). However, apoptotic cells may represent an 
important source of auto-antigens, breaking self-tolerance and 
triggering autoimmune diseases.
NETosis is a fast process of cell death in which neutrophils 
undergoes self-disruption, extruding fibrillary networks com-
posed of DNA, citrullinated histones, and antimicrobial granule 
peptides [neutrophil extracellular traps (NETs)] that entrap and 
may kill bacteria, virus, fungi, and protozoan pathogens. In 
pathological conditions, NETs are associated with tissue damage 
and autoimmune diseases (7, 59, 60). In lupus, apoptosis and 
NETosis are deregulated and overactive, providing an overload 
of self-antigens that under normal circumstances would not be 
available to be targeted by the immune system. In SLE patients, 
the clearance of apoptotic bodies is diminished, as is the capabil-
ity to degrade NETs, related to the reduced DNase I activity (61). 
The increased load of nuclear auto-antigens could amplify the 
autoimmune response in SLE patients. Histone post-translational 
modifications in incompletely cleared apoptotic cells or NETs 
may generate neoantigens and danger signals with an increased 
antigenic and immunogenic potential (7, 59, 60).
Systemic lupus erythematous patients commonly present 
skin photosensitivity. Keratinocytes upon sun exposure undergo 
apoptosis and expel subcellular blebs, which trigger the produc-
tion of specific autoantibodies against DNA and nucleosomes. 
SLE patients also present impairment in the clearance of apototic 
debris by phagocytic cells (58).
C1q and other proteins, such as immunoglobulins, MBL, 
serum amyloid P, and C-reactive protein, can influence the 
adequate removal of apoptotic material, which may be dysfunc-
tional in some SLE patients due to gene polymorphism (7, 59, 
60). Macrophages of SLE patients may have defective uptake of 
apoptotic material (62). The expression of FcγRII and FcγRIII 
receptors on the monocyte plasma membrane is diminished 
in monocytes from SLE patients, which may contribute to 
the impaired clearance of apoptotic debris (63). Complement 
receptor 1 (CR1 and CD35) present in erythrocytes and other 
leukocytes is important for the clearance of circulating immune 
complexes. In SLE patients, the expression of CR1 on erythro-
cytes is also lower when compared to blood cells from normal 
individuals. This could be a factor that contributes to a defective 
clearance of C3b- or C4b-coated immune complexes from the 
circulation (64).
C1q plays an important role since it binds to apoptotic debris 
and accelerates the removal of auto-antigens from the immune 
system (55). Moreover, C1q-deficient and C4-deficient mice 
present impaired uptake of apoptotic bodies by elicited peritoneal 
macrophages when compared to wild type control (56). In addi-
tion, monocytes not only secrete C1q, C1r, and C1s, as it has at its 
membrane a functional anchored C1q with globular heads out-
ward that could assemble C1r/C1s, serving to capture apoptotic 
cells, immune complexes, and pathogen- and danger-associated 
molecular patterns (PAMPs and DAMPs). Monocytes can also 
recognize these patterns by cC1qR (receptor for collagen domain 
of C1q) and gC1qR (receptor for globular domain of C1q) trig-
gering different intracellular signaling pathways (65). Membrane 
C1q and C1qR on monocytes have been suggested to function 
as sensing molecules, switching them to DCs or macrophages, 
depending on the stimuli (66).
Dendritic cells have an important role in preventing autoim-
mune reactions. The tolerance induction is not fully understood 
but depends on DC phenotype, type and dose of antigens, 
cytokine microenvironment, and local synthesis of C1q and 
its receptors (66, 67). C1q could provide active protection by 
regulating autoreactive immune cells. Experiments in vitro have 
shown that C1q inhibits T cell proliferation through gC1q/C1q 
interactions (66, 68, 69).
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iMMUnODeFiCienCieS OF 
COMPLeMenT AnD SLe
According to the European Society for Immunodeficiencies 
(ESID) registry, deficiencies of complement proteins were 
responsible for 4.9% (946 out of 19,355) of all primary immu-
nodeficiencies (PID) between 2004 and 2014 (http://esid.org/
Working-Parties/Registry/ESID-Database-Statistics). Turley et al. 
(70), studying 77 complement-deficient patients from the ESID 
registry in 18 European cities observed that 43% presented defects 
in the CP, 31% in the AP, and 26% presented defects in terminal 
complement components. C2 deficiency was the most common 
of the observed deficiencies (29% of the total). In this series, 37% 
of patients with defects in the CP have SLE-like disease. These 
immunodeficiencies were implicated in higher susceptibility to 
infections: mainly pneumococcal in patients with the CP defects 
and meningococcal disease in patients with terminal component 
defects (70).
Since complement-activation products lead to an accentuated 
inflammatory response in SLE, the disruption of complement 
activity associated with pathological changes in autoimmune 
diseases is considered a paradox. Deficiency of early complement 
components frequently leads to the development of autoimmun-
ity or autoimmune-like manifestations (93% of individuals with 
C1q deficiency, 60–66% of individuals with C1s–C1r deficiency, 
75% of individuals with C4 deficiency, and 10% of individuals 
with C2 deficiency) (71). Inflammatory and autoimmune dis-
eases were not usually seen in patients deficient in proteins from 
the terminal pathway. On the on hand, late complement factor 
deficiencies are preferentially linked to infections and not to auto-
immunity (72, 73). On the other hand, homozygous complement 
deficiency occurs in approximately 1% of SLE patients (74), while 
8% of Brazilian and 20% of Indian JSLE subgroup patients have 
deficiencies of early complement components (75, 76).
C1q, C1r, OR C1s DeFiCienCieS
C1q can recognize a broad range of ligands, from PAMPs to 
DAMPs, and have been explored as a possible major bridge 
between innate and acquired immunity. Patients with C1 defi-
ciencies usually present SLE at an early age, in similar female:male 
proportions, with severe symptoms and prominent cutaneous 
manifestations (77). Defects in C1 complex proteins are related to 
point mutations, gene polymorphism, and partial gene deletion 
(19, 78, 79). Combined deficiencies of C1s/C1r are commonly 
inherited together. More than 50% of these patients develop SLE. 
Sixty-seven cases of complete C1q deficiency have been reported 
(80). More than 90% of patients with homozygous deficiency 
of C1q are reported to have SLE or lupus-like syndrome. Rash 
(95%), glomerulonephritis (42%), and alterations in the central 
nervous system are observed in 18% of C1q-deficient patients. 
High titers of autoantibodies are observed in more than 70% of 
these patients (19–21, 78). Successful cure of C1q deficiency was 
reported with hematopoietic stem cells transplantation in three 
patients, but one died in consequence of graft-versus-host disease 
and multi-organ failure (81–83).
C1q AUTOAnTiBODieS AnD SLe
C1q autoantibodies are present in 2–8% of the healthy popula-
tion, but in SLE, they are present in 30–48% of patients (84). The 
presence of anti-C1q autoantibodies is accompanied by intense 
activation of the CP, with very low titers of C1q, C4, and C2 (85). 
These autoantibodies target a neoepitope of bound C1q that is 
not expressed in the intact C1 complex (8). This helps to explain 
the strong association with C1q autoantibodies and nephritis. 
Their titer correlates to active renal disease with a sensitivity of 
44–100% and a specificity of 70–92% (86).
C2 DeFiCienCY
Homozygous C2 deficiency is more frequent in Western 
European populations with a prevalence of 1:10,000–20,000, in 
which the majority (>60%) of these individuals are asympto-
matic. Heterozygous C2 deficiency has a frequency of 1–2% in 
Caucasian populations (19, 87). About 10–30% of homozygous 
C2-deficient patients develop SLE (19, 88, 89). C2-deficient 
patients present SLE with a female:male proportion of 7:1. 
Arthritis, malar rash, discoid rash, and photosensitivity are seen 
in the majority of C2-deficient patients with SLE (19, 20, 22, 
78, 89). The human C2 gene is located in chromosome 6p21.3. 
Type I C2 deficiency is caused by a 28-bp deletion in the C2 
gene, which results in the deletion of exon 6 and no translation 
of the C2 protein. Type II C2 deficiency is usually caused by 
a point mutation (Ser189Phe and Gly144Arg), which leads to an 
impairment in C2 secretion (87, 90), reducing the plasma levels 
of this protein.
C4 DeFiCienCY
Complete homozygous deficiency of C4 is rare but is strongly 
related to SLE. More than 75% of these patients develop this 
disease. C4 genes are located in chromosome 6p21.3 in the 
MHC Class III cluster, with two genes encoding C4 protein 
(C4A and C4B) (91). The gene copy number (CNV) of C4 
ranges from 2 to 8. The more common CNV in the healthy 
population is 2 of each isotype codominantly expressed. SLE 
is related to reduction of total C4 copy number, but increased 
number of copies is a protective factor (91, 92). Approximately 
50% of SLE-C4-deficient patients develop glomerulonephritis 
and more than 70% carry ANA and anti-Rho autoantibodies in 
their serum (19, 20, 78).
The clinical characteristics, prevalence, and presence of 
autoantibodies in patients with deficiency of early components 
of the CP are summarized in Table 2 (8, 19–22).
SLe, CLASSiCAL COMPLeMenT 
COMPOnenT DeFiCienCieS, AnD 
MORTALiTY
Systemic lupus erythematous patients with deficiencies in clas-
sical complement components present disease at an early age, 
with more aggressive symptoms and worse prognosis. Walport 
TABLe 2 | Clinical characteristics and prevalence of patients with early complement component deficiencies (8, 19–21).
C deficiency Global prevalence SLe/SLe-like and  
complement deficiency
Clinical characteristics Autoantibody positivity
Clq Few cases 90–93% Rash 95% ANA 75%
Glomerulonephritis 42% ENA (Sm, RNP, Ro, and/or La) 70%
Central nervous system 18% DNAds antibody 20%
Clr/Cls Few cases 50–57% Cutaneous 90% ANA 75%
Glomerulonephritis 50% ENA (Sm, RNP, Ro, and/or La) 70%
C4 Few cases 75% Glomerulonephritis 50% ANA 75%
Anti-Ro 70% (with anti-La negative)
DNAds antibody 18%
C2 1:10,000–20,000 (homozygous) 
1–2% (heterozygous)
10% (homozygous) 2.4–5.8% 
(heterozygous)
Arthritis 83%
Malar rash 92%
Discoid rash 67%
Photosensitivity 67%  
Serositis 42%
ANA low titer 25–55%
DNAds antibody 33%
Anti-Ro 25–50%, 77% (pickering)
Anti-histone antibody 20%
Anti-Clq 2–8% 30–60%
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et al. (21) reviewed a series of 41 C1q deficiency cases reported 
in the literature, 38 of which were SLE patients. In these SLE 
cases, eight individuals younger than 10  years of age died and 
four of them due of sepsis. Kallel-Sellami et al. (22) reported a 
3-year-old girl with SLE and C1q deficiency who died of digestive 
hemorrhage during treatment of infection. Schaarenburg et  al. 
described 20% fatality in C1q-deficient patients before age of 
20 years (93). Jesus et al. (75) studied a total of 72 JLES patients 
of which six were complement-deficient patients. Three of the six 
deaths occurred in patients deficient in CP proteins, compared 
with 1 out of 59 (1.7%) in the group without PID. Two deaths 
were caused by sepsis, and the third was caused by pneumococcal 
meningitis. In the same study, disease activity and severity over 
time, measured by SLICC–ACR damage index, were significantly 
greater in PID patients (including deficiency of early components 
of complement and/or immunoglobulins). These descriptions of 
severe infections in reported cases emphasize the role of the CP in 
early childhood, when protective antibodies and the anamnestic 
response have not yet developed. Taken together, these reports 
reinforce the severity of disease in young SLE patients with 
 complement immunodeficiencies of the CP.
FinAL COnSiDeRATiOnS
Systemic lupus erythematous is more severe when associated with 
deficiencies in components of the CP mainly in young patients. 
We still do not fully comprehend the real prevalence of comple-
ment deficiencies and their association with SLE.
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